FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

For research purposes only. Full disclaimer →

Research/Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.
Back to Research Library
GLP1-RALiraglutideSemaglutide

Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.

May 17, 2026
Share

Source Paper

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen Anders Boisen et al.Obesity surgery2023
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

GLP-1 Receptor Agonists Show Promise in Tackling Weight Regain After Bariatric Surgery

Published: May 17, 2026 | Source: Obesity surgery (2023) | Category: GLP1-RA, Liraglutide, Semaglutide

Overview

A recent study published in Obesity Surgery suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide and semaglutide, can help patients who have regained weight after bariatric surgery to lose a significant portion of the regained weight within six months. This finding is crucial for those seeking effective treatments for weight regain following surgical interventions.

Study Background

Weight regain after bariatric surgery is a common issue, affecting up to one-third of patients. While GLP-1 RAs are known to be effective in managing type 2 diabetes and obesity, their role in treating weight regain specifically after bariatric surgery was less clear until now. This retrospective observational study aimed to fill this knowledge gap by examining the efficacy of liraglutide and semaglutide for patients who had regained weight post-surgery.

What the Research Found

The study involved 50 patients (82% female) at a Swiss bariatric reference center, with an average age of 47 years. Before treatment with GLP-1 RAs, these patients had an average body weight of 90.5 kg and a BMI of 34.0 kg/m². After six months of treatment (liraglutide: n=29; semaglutide: n=21), the median weight loss was substantial, with two-thirds of the regained weight being lost.

What This Means for Peptide Users

For individuals who have experienced weight regain after bariatric surgery, this study provides hope and a new therapeutic option. GLP-1 RAs can be an effective tool in helping these patients achieve significant weight loss, thereby improving their overall health outcomes and reducing the risk of obesity-related complications.

Limitations and Caveats

While promising, this study has several limitations that must be acknowledged. It was conducted at a single center with a relatively small sample size, which limits its generalizability to broader populations. Additionally, the retrospective nature of the research means there could be uncontrolled variables influencing the results. Randomized controlled trials are needed to confirm these findings and establish GLP-1 RAs as standard treatment options for weight regain after bariatric surgery.

How This Compares to Previous Research

Previous studies have highlighted the efficacy of GLP-1 RAs in treating obesity and type 2 diabetes, but this is one of the first to focus specifically on their role in managing weight regain post-bariatric surgery. The results align with earlier research showing that these peptides can induce significant weight loss, although the specific context of bariatric surgery adds a new dimension to our understanding.

Our Analysis

PeptideVault views this study as an important step forward in addressing the challenges faced by patients who experience weight regain after bariatric surgery. The findings are encouraging and provide a basis for further research. However, due to the limitations mentioned, it is crucial that future studies employ randomized controlled trial designs to validate these results.

Key Takeaways

  • GLP-1 RAs can help patients lose significant amounts of regained weight within six months after bariatric surgery.
  • The study highlights a need for larger-scale clinical trials to confirm the efficacy and safety of GLP-1 RAs in this specific patient population.
  • For now, healthcare providers should consider these findings as part of an evolving understanding of GLP-1 RA's potential benefits beyond traditional indications like diabetes and obesity.

Original Source

Citation: Jensen Anders Boisen, Renström Frida, Aczél Stefan et al. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.. Obesity surgery. DOI: 10.1007/s11695-023-06484-8

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.